Welcome to our dedicated page for Protagonist Ther news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Ther stock.
News about Protagonist Therapeutics, Inc. (NASDAQ: PTGX) centers on its progress as a discovery-through-late-stage development biopharmaceutical company advancing peptide-based drug candidates. Company announcements frequently highlight clinical and regulatory milestones for its lead investigational therapies, icotrokinra and rusfertide, as well as updates from its broader pipeline and collaborations.
Investors following PTGX news will see regular coverage of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. Press releases describe data from Phase 3 ICONIC studies in moderate-to-severe plaque psoriasis, including ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2, as well as the Phase 2b ANTHEM-UC trial in ulcerative colitis. News items also report on regulatory submissions, such as the New Drug Application to the U.S. FDA and an application to the European Medicines Agency for plaque psoriasis.
Coverage of rusfertide focuses on its development for polycythemia vera in collaboration with Takeda. News releases describe Phase 3 VERIFY study results, long-term extension data from THRIVE, and the submission of a New Drug Application to the FDA for adults with polycythemia vera. These updates often include details on hematocrit control, phlebotomy requirements, patient-reported outcomes, and regulatory designations such as Breakthrough Therapy, Orphan Drug, and Fast Track status.
Additional PTGX news includes presentations at major medical and scientific conferences, such as the American Society of Hematology Annual Meeting, European Academy of Dermatology and Venereology Congress, American College of Gastroenterology meeting, and the J.P. Morgan Healthcare Conference. The company also issues periodic financial result and corporate update releases, which summarize recent clinical achievements, collaboration developments with Johnson & Johnson and Takeda, and progress in earlier-stage programs like PN-881, PN-477, and the oral hepcidin initiative.
For readers tracking PTGX, this news stream provides insight into Protagonist’s clinical data, regulatory interactions, partnership activities, and pipeline evolution as described in its own public communications.
Protagonist Therapeutics (Nasdaq: PTGX) has successfully completed enrollment for its Phase 2 study of rusfertide (PTG-300) in polycythemia vera (PV), exceeding the target of 50 evaluable patients. Those not included will have the chance to participate in the upcoming Phase 3 study. Preliminary data suggests rusfertide can maintain hematocrit levels, reducing thrombotic risks in PV patients. The company plans to present interim findings at a major medical meeting soon and is optimistic about moving into Phase 3 trials in early 2022, backed by regulatory agency support.
Protagonist Therapeutics (PTGX) announced plans to initiate a global Phase 3 clinical trial for rusfertide (PTG-300), targeting polycythemia vera (PV). The FDA provided key feedback, and the EMA expressed support for its clinical development plan. The Phase 3 study will enroll 200-250 adult participants, focusing on the proportion achieving response defined by hematocrit control. Secondary endpoints will include symptoms and phlebotomy frequency. The trial aims to address unmet needs in PV treatment, paving the way for future drug applications in the U.S. and Europe.
Protagonist Therapeutics (Nasdaq: PTGX) reported its financial results for Q4 2020, highlighting significant growth in its pipeline. The company received orphan drug and Fast Track designations for rusfertide in polycythemia vera (PV), affecting approximately 100,000 patients in the U.S. Protagonist aims to finalize its clinical development plan for rusfertide by mid-2021. The company raised $255 million through various public offerings in 2020, ending the year with $307.8 million in cash and equivalents. However, it reported a net loss of $66.2 million for the full year 2020.
Protagonist Therapeutics (Nasdaq: PTGX) will host a conference call on March 10, 2021, at 4:30 PM ET to discuss its Q4 and full year 2020 financial results. The call can be accessed via phone at 1-844-515-9178 (U.S.) or 1-614-999-9313 (International), with conference ID #: 7756175. A live webcast will also be available on the company's website. Protagonist is developing several peptide-based therapeutics, including PTG-300 and PTG-200, currently in various stages of clinical trials.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will participate in the virtual H.C. Wainwright Global Life Sciences Conference from March 9 to 10, 2021. CEO Dinesh V. Patel, Ph.D., will engage in a fireside chat on March 9, starting at 7:00 a.m. EST, with a subsequent opportunity for one-on-one meetings with investors. A webcast of the event will be available for 90 days. Protagonist is advancing multiple peptide-based therapeutics, including PTG-300 and PTG-200, targeting various conditions such as polycythemia vera and Crohn's disease.
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) announced the issuance of an inducement award to Jami Taylor, newly appointed Vice President of Corporate Affairs, on February 26, 2021. The award includes an option to purchase 50,000 shares at an exercise price of $23.57, the closing price on the grant date. The shares vest over four years. This grant is part of the Amended Inducement Plan adopted on May 29, 2018, reflecting the company's commitment to attract top talent. Protagonist is focused on developing peptide-based therapeutics for significant unmet medical needs.
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) will participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference from February 22 to 26, 2021. Dinesh V. Patel, Ph.D., President and CEO, is scheduled for a fireside chat on February 24, 2021, at 10:40 a.m. EST. The event will be available for live and archived viewing on the company’s website. Protagonist, based in Newark, California, focuses on innovative peptide-based therapeutics, with several candidates in clinical trials for conditions like Crohn's disease and polycythemia vera.
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) announced the issuance of an inducement award to Dr. Paula O'Connor, recently appointed as Senior Vice President of Clinical Development. This award includes an option to purchase 75,000 shares of the company’s common stock at an exercise price of $20.71, the closing price on January 29, 2021. The award is designed as a recruitment incentive, with shares vesting over four years. Protagonist Therapeutics focuses on developing peptide-based therapeutics for various medical conditions, with several candidates currently in clinical trials.
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced that CEO Dinesh V. Patel, Ph.D., will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 2:00 p.m. EST. The event will be available via live and archived webcast on their website. Protagonist is a clinical-stage biopharmaceutical company focusing on peptide-based therapeutics, with candidates like PTG-300 and PTG-200 in Phase 2 trials for various conditions, including polycythemia vera and Crohn's disease.
Protagonist Therapeutics (Nasdaq: PTGX) has initiated a Phase 1 study for PN-235, an oral IL-23 receptor antagonist. This study, involving about 100 healthy volunteers, aims to assess the drug's safety and pharmacokinetics. PN-235 is the first oral candidate from a collaboration with Janssen Biotech. The study includes ascending doses and a solid dose comparison, focusing primarily on safety. Protagonist anticipates Phase 1 results in 2021, with potential applications in various diseases. The collaboration allows Protagonist to earn milestone payments as Janssen handles later development phases.
FAQ
What is the current stock price of Protagonist Ther (PTGX)?
What is the market cap of Protagonist Ther (PTGX)?
